重组人可溶性血管内皮细胞生长抑制因子对S-180肉瘤生长的抑制作用

Inhibition Effect of the Recombinant Soluble Vascular Endothelial Growth Inhibitor on the Growth of S-180 Sarcoma in vivo

目的 研究重组人可溶性血管内皮细胞生长抑制因子 (VEGI)对小鼠异体种植 S- 180肉瘤生长的抑制作用。 方法 用不同剂量 VEGI分别治疗皮下和腹腔种植 S- 180肉瘤的小鼠 ,连续 7天。 30天后处死小鼠 ,剥离肿瘤并称重 ,计算每组平均瘤重和抑瘤率 ;记录腹腔种植组小鼠的死亡时间 ,观察治疗制剂对小鼠寿命的影响。采用免疫组织化学 Envision二步法对肿瘤组织进行分析。 结果 VEGI治疗组 (5 .0 ,10 .0 ,2 0 .0μg/ kg)的平均瘤重分别为 2 .92± 2 .0 5 g,1.92± 0 .31g和 1.0 6± 0 .0 5 g,明显小于 PBS对照组 (10 .33± 2 .15 g,P<0 .0 1) ,抑瘤率分别为 71.73% ,81.41%和 89.74% ;并可明显延长腹腔荷 S- 180肉瘤小鼠的生存时间 (P<0 .0 1)。每 mm2 肿瘤组织切片中 ,VEGI治疗组 (10 .0μg/ kg)的阳性血管内皮细胞数为 117± 10个 ,PBS对照组 2 41± 34个 (P<0 .0 5 )。 结论 VEGI通过抑制体内肿瘤组织中血管的生成抑制了恶性肿瘤的生长 ,显示出显著的抗肿瘤活性。

Objective To test the anti tumor activity of recombinant soluble vascular endothelial growth inhibitor(VEGI) against S 180 sarcoma in a murine model. Methods The mice with S 180 sarcoma xenograft implanted into the subcutaneous tissue and abdominal cavity were treated once every day with different doses of the recombinant soluble VEGI for 7 days. The tumor weight of subcutaneous S 180 sarcoma was measured after 30 days and the life expectancy of mice bearing S 180 sarcoma in abdominal cavity was recorded. The tumor tissue was examined by immunohistochemistry with envision technique. Results The mean tumor weight in recombinant soluble VEGI treated groups(5 0, 10 0, 20 0 μg/kg) were 2 92±2 05 g, 1 92±0 31 g and 1 06±0 05 g, respectively, being smaller than that of the control group was 10 33±2 15 g. Calculated by weight, the tumor growth was inhibited by 71 73%, 81 41% and 89 74%, respectively. In addition, administration of the recombinant soluble VEGI could extend the life expectancy of mice bearing S 180 sarcoma(P<0 01). The number of the endothelial cells in the tumor after treated by 10 0 μg/kg recombinant soluble VEGI was 117±10/mm 2(×40), less than that of the control group(241±34/mm 2, P<0 05). Conclusion Recombinant soluble VEGI could inhibit the growth of S 180 sarcoma in vivo through inhibiting the proliferation of endothelial cells in tumor.